- Home
- MYGN vs NAVI Comparison
MYGN vs NAVI Comparison
Compare MYGN & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- NAVI
- Stock Information
- Founded
- MYGN 1991
- NAVI 1973
- Country
- MYGN United States
- NAVI United States
- Employees
- MYGN N/A
- NAVI N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NAVI Investment Bankers/Brokers/Service
- Sector
- MYGN Health Care
- NAVI Finance
- Exchange
- MYGN Nasdaq
- NAVI Nasdaq
- Market Cap
- MYGN 2.0B
- NAVI 1.7B
- IPO Year
- MYGN 1995
- NAVI N/A
- Fundamental
- Price
- MYGN $13.69
- NAVI $14.44
- Analyst Decision
- MYGN Hold
- NAVI Sell
- Analyst Count
- MYGN 12
- NAVI 8
- Target Price
- MYGN $23.92
- NAVI $14.63
- AVG Volume (30 Days)
- MYGN 904.0K
- NAVI 898.7K
- Earning Date
- MYGN 11-07-2024
- NAVI 01-29-2025
- Dividend Yield
- MYGN N/A
- NAVI 4.40%
- EPS Growth
- MYGN N/A
- NAVI N/A
- EPS
- MYGN N/A
- NAVI 0.70
- Revenue
- MYGN $823,600,000.00
- NAVI $1,036,000,000.00
- Revenue This Year
- MYGN $13.82
- NAVI N/A
- Revenue Next Year
- MYGN $4.59
- NAVI $1.01
- P/E Ratio
- MYGN N/A
- NAVI $20.86
- Revenue Growth
- MYGN 12.15
- NAVI N/A
- 52 Week Low
- MYGN $13.81
- NAVI $13.71
- 52 Week High
- MYGN $29.30
- NAVI $19.44
- Technical
- Relative Strength Index (RSI)
- MYGN 26.49
- NAVI 43.14
- Support Level
- MYGN $13.92
- NAVI $14.52
- Resistance Level
- MYGN $15.44
- NAVI $15.26
- Average True Range (ATR)
- MYGN 0.79
- NAVI 0.35
- MACD
- MYGN 0.03
- NAVI -0.06
- Stochastic Oscillator
- MYGN 3.06
- NAVI 12.74
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance and business processing solutions that simplify complex programs and help millions of people achieve success. It operates business in three segments: Federal Education Loans, Consumer Lending and Business Processing.